Apellis Pharmaceuticals Inc
(NAS:APLS)
$
28.075
-0.485 (-1.7%)
Market Cap: 3.49 Bil
Enterprise Value: 3.59 Bil
PE Ratio: 0
PB Ratio: 12.94
GF Score: 42/100 Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 12:00PM GMT
Release Date Price:
$60.91
(+3.61%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. Good morning, everyone, and thanks for joining us at the Goldman Sachs Global Healthcare Conference. We're really thrilled to be joined this morning by the team from Apellis Pharmaceuticals to get an update on things kind of at an really interesting crossroads for the company. So really just so thrilled to have them with us today.
Questions & Answers
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
So let's start at a big picture level. So if, Cedric, if you can walk through the current clinical pipeline and the current kind of technological approach Apellis has for the treatment of complement-mediated diseases, that would be great, particularly focusing on ongoing and upcoming clinical trials.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Sure. Thank you so much, Madhu. So for those people new to Apellis, to understand the company,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot